Affiliation:
1. Washington State University, Spokane, WA, USA
Abstract
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.
Subject
Pharmacology (medical),Pharmacology,Pharmacy
Reference17 articles.
1. Rezurock (belumosudil) [prescribing information]. Warrendale, PA: Kadmon Pharmaceuticals LLC; July 2021.
2. Evolving Therapeutic Options for Chronic Graft‐versus‐Host Disease
3. Imbruvica (ibrutinib) [prescribing information]. Sunnyvale, CA: Pharmacyclics LLC; December 2020.
4. National Institutes of Health. Belumosudil OR KD025. ClinicalTrials.gov. Accessed August 30, 2021. https://clinicaltrials.gov/ct2/results?cond=&term=belumosudil+OR+kd025&cntry=&state=&city=&dist=
5. ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease